Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares, rose in value, with the stock price down by -8.71% to the previous day’s close as strong demand from buyers drove the stock to $15.19.
Actively observing the price movement in the last trading, the stock closed the session at $16.64. Referring to stock’s 52-week performance, its high was $17.85, and the low was $9.67. On the whole, DAWN has fluctuated by 1.13% over the past month.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that DAWN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of DAWN currently trading nearly 0.99% and -0.25% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.89, while the 7-day volatility ratio is showing 10.48% which for the 30-day chart, stands at 6.56%. Furthermore, Day One Biopharmaceuticals Inc (DAWN)’s beta value is -1.44, and its average true range (ATR) is 1.04.
A comparison of Day One Biopharmaceuticals Inc (DAWN) with its peers suggests the former has fared considerably weaker in the market. DAWN showed an intraday change of -8.71% in last session, and over the past year, it grew by 10.80%%.
Data on historical trading for Day One Biopharmaceuticals Inc (NASDAQ:DAWN) indicates that the trading volumes over the past 3 months, they’ve averaged 791.97K. According to company’s latest data on outstanding shares, there are 87.23 million shares outstanding.
Nearly 32.55% of Day One Biopharmaceuticals Inc’s shares belong to company insiders and institutional investors own 76.24% of the company’s shares. The stock has risen by 4.04% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DAWN stock heading into the next quarter.
